Mayo Clinic ‘cautiously optimistic’ on Biogen’s Alzheimer’s drug

BAN2401 will be one of several drugs targeting beta amyloid, a protein in which forms toxic brain plaques in which are theoretically an underlying cause of the memory-robbing disease.

There will be still no treatment in which can slow the progression of Alzheimer’s, the commonest form of dementia. Current drugs can do no more than ease some of the symptoms.

If This specific latest treatment will be ultimately successful, the item might be “major step forward,” Peterson said on “Power Lunch.”

“Cure will be probably an overrated goal for Alzheimer’s disease although if we could delay the onset of the symptoms, slow the progression of the disease in which might be huge for patients,” he added.

However, Peterson noted in which right currently only top-line results through the study have been released. Biogen along with Eisai are supposed to Discharge the detailed results of the final analysis of the midstage trial at future conferences.

In a statement Thursday, Biogen’s chief medical officer, Dr. Alfred Sandrock, called the prospect of being able to offer meaningful disease-modifying therapies for Alzheimer’s “both exciting along with humbling.”

“These BAN2401 18-month data offer important insights inside investigation of potential treatment options for patients with Alzheimer’s disease along with underscores in which neurodegenerative diseases may not be as intractable as they once seemed,” he said.

Currently, 5.7 million Americans are living with Alzheimer’s along with in which number will be supposed to rise, according to the Alzheimer’s Association. By 2050, the item’s projected to reach nearly 14 million people inside U.S.

— CNBC’s Tae Kim along with Reuters contributed to This specific report.

Leave a Reply

Your email address will not be published. Required fields are marked *


12 − five =